DexCom, Inc.

NasdaqGS:DXCM Rapport sur les actions

Capitalisation boursière : US$28.4b

DexCom Croissance future

Future contrôle des critères 4/6

DexCom devrait augmenter ses bénéfices et son chiffre d'affaires de 16.8% et de 13.3% par an respectivement. Le BPA devrait croître de de 16.1% par an. Le rendement des capitaux propres devrait être 24.8% dans 3 ans.

Informations clés

16.8%

Taux de croissance des bénéfices

16.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices17.1%
Taux de croissance des recettes13.3%
Rendement futur des capitaux propres24.8%
Couverture par les analystes

Good

Dernière mise à jour22 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Nov 08
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

Oct 21
DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Sep 30
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Sep 16
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:DXCM - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20265,3119531,0011,35821
12/31/20254,6017817981,13724
12/31/20244,01663460393724
9/30/20243,954681535822N/A
6/30/20243,935667666891N/A
3/31/20243,802639584802N/A
12/31/20233,622542512749N/A
9/30/20233,403377500747N/A
6/30/20233,198358466771N/A
3/31/20233,023293416754N/A
12/31/20222,910341305670N/A
9/30/20222,793244261643N/A
6/30/20222,673230216597N/A
3/31/20222,57225895486N/A
12/31/20212,44921753443N/A
9/30/20212,319577140509N/A
6/30/20212,170562101409N/A
3/31/20212,027530236502N/A
12/31/20201,927550277476N/A
9/30/20201,821231264447N/A
6/30/20201,716205209394N/A
3/31/20201,601148131305N/A
12/31/20191,476101135315N/A
9/30/20191,351-17151205N/A
6/30/20191,222-17039167N/A
3/31/20191,128-13053144N/A
12/31/20181,032-12756123N/A
9/30/20189154364131N/A
6/30/2018833-5N/A110N/A
3/31/2018761-33N/A83N/A
12/31/2017719-50N/A92N/A
9/30/2017669-48N/A64N/A
6/30/2017633-65N/A51N/A
3/31/2017599-88N/A57N/A
12/31/2016573-66N/A56N/A
9/30/2016533-57N/A54N/A
6/30/2016490-80N/A49N/A
3/31/2016445-64N/A45N/A
12/31/2015402-58N/A49N/A
9/30/2015356-58N/A46N/A
6/30/2015319-20N/A40N/A
3/31/2015285-23N/A29N/A
12/31/2014259-22N/A24N/A
9/30/2014227-26N/A20N/A
6/30/2014201-27N/A10N/A
3/31/2014178-31N/A5N/A
12/31/2013160-30N/A2N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DXCM ( 16.8% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de DXCM ( 16.8% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de DXCM devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DXCM ( 13.3% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DXCM ( 13.3% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de DXCM devrait être élevé dans 3 ans ( 24.8 %)


Découvrir les entreprises en croissance